Nachrichten zur ImmunityBio Inc. Aktie

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.…

Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That”

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the stocks Jim Cramer talked about, along with market froth. When a caller asked…

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the companys heavily-shorted stock.…

ImmunityBio Inc.: Immuntherapien der nächsten Generation - D. Boral Capital sieht 259 % Kurspotenzial

Revolutionäre Immunmodulation als Kernkompetenz ImmunityBio Inc. (IBRX) hat sich von einem klassischen Biotech-Forschungsunternehmen zu einem kommerziellen Akteur im Bereich der…

ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

Why ImmunityBio Stock Is Skyrocketing Again Today

It has been an incredible week of positive news for ImmunityBio.…

Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more

These are the stocks posting the largest moves in premarket trading.…

ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma

Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses…

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This…

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ImmunityBio (IBRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

ImmunityBio Inc. (IBRX): H.C. Wainwright sieht Potenzial für ANKTIVA bei therapieresistenten nicht-muskelinvasiven Blasenkrebserkrankungen

ImmunityBio Inc. (IBRX) (i.) ist ein Biotechnologieunternehmen, das sich auf die Entwicklung von Next-Generation-Therapien und Impfstoffen konzentriert, die das natürliche…

ImmunityBio shares surge following progress in FDA discussions By Investing.com

ImmunityBio shares surge following progress in FDA discussions…

ImmunityBios Cash Burn And Dilution Dampen Anktivas Potential

…

Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move

Biotech billionaire Patrick Soon-Shiong was accused in a shareholder lawsuit of misleading ImmunityBio Inc. investors about the prospects of the…

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…